Emactuzumab clinical trials
Also written RO5509554 and RG7155.
How each study uses emactuzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2011 (1)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Hoffmann-La Roche (2) · SynOx Therapeutics Limited (1) · M.D. Anderson Cancer Center (1)
Studies
Open first, then newest update. How each study uses emactuzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)Active, not recruitingPhase 3SynOx Therapeutics LimitedNCT05417789Written as Emactuzumab
- Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedPhase 2M.D. Anderson Cancer CenterNCT02923739Written as Emactuzumab
- A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid TumorsCompletedPhase 1Hoffmann-La RocheNCT02323191Written as Emactuzumab
- A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid TumorsCompletedPhase 1Hoffmann-La RocheNCT01494688Written as RO5509554
Given beside what is tested · 3 — emactuzumab is usual care or a partner of the new treatment
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingPhase 3Hoffmann-La RocheNCT03768063Written as Emactuzumab
- A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid TumorsCompletedPhase 1Hoffmann-La RocheNCT02760797Written as Emactuzumab
- A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin LymphomaWithdrawnPhase 1Hoffmann-La RocheNCT03369964Written as Emactuzumab
Codes
What other systems call emactuzumab · ClinicalTrials.gg INT000333
- MeSH (NLM) C000602304emactuzumabOne source NLM
- UNII (FDA) 6FY6EI1X8REMACTUZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q25326691EmactuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C125548EmactuzumabOne source FDA
- DrugBank DB14905One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000602304 | emactuzumab | One source NLM |
| UNII (FDA) | 6FY6EI1X8R | EMACTUZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q25326691 | Emactuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C125548 | Emactuzumab | One source FDA |
| DrugBank | DB14905 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.